By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Where Great Emphasis is Put on Research.

Sanofi purchases biotech company in Austria

Wolfgang Kaps, Managing Director Country Chair Austria, General Manager Sanofi Genzyme Austria © Sanofi

This biotechnology company headquartered in Vienna specialises in skin diseases. Origimm's most important product is a vaccine-based immunotherapy against acne which is currently in the test phase. According to Sanofi, Origimm complements its own research platform for mRNA vaccines.

Following its termination of diabetes research, Sanofi considers the immune business to be one of its main pillars. Sanofi aims to more than double its vaccine sales by the end of the decade. Its focus will be on vaccines against the flu and meningitis as well as polio and booster shots. Sanofi expects to have ten vaccines in clinical studies by the year 2025, of which six will be mRNA vaccines.

Continue reading and learn more about life sciences research in Austria!

Read more:

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin



Meet us at events, seminars and trade shows - worldwide.

  • AAIC - AI in AgriTech

    25.01.2022 - 26.01.2022, virtual

  • ROBOTICS Slovenia 2022

    15.02.2022 - 17.02.2022, Ljubljana, Slovenia

Austria Map

Find the perfect location for your company

Austria offers the comfort and infrastracture of a western industrial nation. The high quality of life is an advantage when it comes to attracting top executives from around the world to our headquarters here.

Coca-Cola Austria

More testimonials

news from the business location Austria

The path taken by immune cells

In order to combat infections and heal injuries as well as to fight against tumours, immune cells need to enter tissue.

IPCEI on Microelectronics – NXP Contributes Security Technology

Important Projects of Common European Interest (IPCEI) are large-scale innovation programmes in which several EU member states participate. They are designed to sustainably strengthen European value chains in critical technology sectors. Microelectronics comprises one such key technology. Within the context of the IPCEI on Microelectronics, NXP Gratkorn is focusing on the issue of “security,” thus contributing to Europe’s digital sovereignty and the resilience of its critical infrastructures.

More news All blog posts